Dave Lemus

Dave Lemus is a Non-Executive Director at Silence Therapeutics Plc. Dave was previously the Chief Executive Officer & Chief Financial Officer at Ironshore Pharmaceuticals Inc. from January 2020 to April 2022. During their tenure, sales increased approx. 3X, and market share 2X. Dave achieved signficantly lower cash burn and increased operational gains through internalization of the sales force, renegotiation of key vendor agreements, improvement of commercial & government payor access, and outsourcing/automation of key SG&A processes.

From December 2015 to May 2017, Dave was the Chief Operating Officer and Chief Financial Officer at Medigene AG. Dave stepped down from the Board as Vice Chair for a 2 yr. assignment to assist in executive management transition. Dave successfully negotiated and closed the Company's $1 bil. T-Cell receptor platform technology deal with Bluebird Bio, which was ranked by BIO as one of the largest R&D biotech/pharma deals in 2016.

Dave was the Chief Executive Officer at Sigma-Tau Pharmaceuticals, Inc. from July 2011 to August 2015.

Dave Lemus has a Masters in Business Administration from the Massachusetts Institute of Technology and a Bachelor of Science in Accounting from the University of Maryland. Dave is also a Certified Public Accountant in the state of Maryland.